Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

The number of cases of severe dengue disease continues to grow in endemic areas of
southeast Asia, Central and South America, and other subtropical regions. Children bear the …

Importance Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and
serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 …

Background Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P.
falciparum and P. vivax, respectively, are leading candidates for vaccines preventing …

The recombinant dengue virus type-4 vaccine candidate 2A30 was attenuated in rhesus
monkeys due to an engineered 30-nucleotide deletion in the 3-untranslated region of the viral …

Apical membrane antigen 1 (AMA1), a polymorphic merozoite surface protein, is a leading
blood-stage malaria vaccine candidate. A phase 1 trial was conducted with 30 malaria-…

Plasmodium vivax is responsible for the majority of malaria cases outside of Africa, and
results in substantial morbidity. Transmission blocking vaccines are a potentially powerful …

In vitro studies have attempted to identify dengue virus (DEN) target cells in peripheral blood;
however, extensive phenotyping of peripheral blood mononuclear cells (PBMCs) from …

A dengue human challenge model can be an important tool to identify candidate dengue
vaccines that should be further evaluated in large efficacy trials in endemic areas. Dengue is …

Background. The 4 serotypes of dengue virus, DENV-1–4, are the leading cause of arboviral
disease globally. The ideal dengue vaccine would provide protection against all serotypes …